APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Autologous Stem Cell & Non-stem Cell Therapies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Autologous Stem Cell & Non-stem Cell Therapies Market Analysis and Forecast 2026-2032

Report ID 17407212023 May 2026183 pages

Choose your research edition.

Industry ResearchAutologous Stem Cell & Non-stem Cell Therapies Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Autologous Stem Cell & Non-stem Cell Therapies Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Autologous Stem Cell & Non-stem Cell Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Autologous Stem Cell & Non-stem Cell Therapies Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Autologous Stem Cell & Non-stem Cell Therapies Market Analysis and Forecast 2026-2032183 pages · $4,950 USD

Market perspective

The global Autologous Stem Cell & Non-stem Cell Therapies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Autologous Stem Cell & Non-stem Cell Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Autologous Stem Cell & Non-stem Cell Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Autologous Stem Cell & Non-stem Cell Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Autologous Stem Cell & Non-stem Cell Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Autologous Stem Cell & Non-stem Cell Therapies include Anterogen Co., Ltd., APAC Biotech, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.), Gilead Sciences, Inc., Green Cross Holdings Co., Ltd. (GC Cell), Healiva SA and ImmunoACT, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Autologous Stem Cell & Non-stem Cell Therapies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Autologous Stem Cell & Non-stem Cell Therapies, also provides the revenue of main regions and countries. Of the upcoming market potential for Autologous Stem Cell & Non-stem Cell Therapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Autologous Stem Cell & Non-stem Cell Therapies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Autologous Stem Cell & Non-stem Cell Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Autologous Stem Cell & Non-stem Cell Therapies revenue, projected growth trends, production technology, application and end-user industry.

Autologous Stem Cell & Non-stem Cell Therapies Segment by Company

Anterogen Co., Ltd.

APAC Biotech

Bristol-Myers Squibb Company

CARsgen Therapeutics Holdings Limited

Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Gilead Sciences, Inc.

Green Cross Holdings Co., Ltd. (GC Cell)

Healiva SA

ImmunoACT

Iaso Biotherapeutics

Johnson & Johnson

Lovance Biotherapeutics, Inc.

Novartis AG

Pharmicell Co., Ltd.

Regrow Biosciences Pvt Ltd.

Tegoscience

Vericel Corporation

W (Cayman) Therapeutics Co. Ltd.

Autologous Stem Cell & Non-stem Cell Therapies Segment by Type

CAR-T

Tumor Infiltrating Lymphocyte

Autologous Stem Cell & Non-stem Cell Therapies Segment by Application

Hospital

Surgery Center

Other

Autologous Stem Cell & Non-stem Cell Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autologous Stem Cell & Non-stem Cell Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Autologous Stem Cell & Non-stem Cell Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autologous Stem Cell & Non-stem Cell Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Autologous Stem Cell & Non-stem Cell Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Autologous Stem Cell & Non-stem Cell Therapies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Autologous Stem Cell & Non-stem Cell Therapies revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CAR-T Major Player Table 3. Tumor Infiltrating Lymphocyte Major Player Table 4. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Surgery Center Major Player Table 7. Other Major Player Table 8. Autologous Stem Cell & Non-stem Cell Therapies Industry Trends Table 9. Autologous Stem Cell & Non-stem Cell Therapies Industry Drivers Table 10. Autologous Stem Cell & Non-stem Cell Therapies Industry Opportunities and Challenges Table 11. Autologous Stem Cell & Non-stem Cell Therapies Industry Restraints Table 12. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Region (2021-2026) Table 15. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Region (2027-2032) Table 17. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Players (2021-2026) Table 19. Global Autologous Stem Cell & Non-stem Cell Therapies Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Autologous Stem Cell & Non-stem Cell Therapies Key Players Headquarters & Area Served Table 21. Global Autologous Stem Cell & Non-stem Cell Therapies Players, Product Type & Application Table 22. Global Autologous Stem Cell & Non-stem Cell Therapies Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Autologous Stem Cell & Non-stem Cell Therapies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Type (2021-2026) Table 29. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Type (2027-2032) Table 30. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Application (2021-2026) Table 34. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Application (2027-2032) Table 35. Anterogen Co., Ltd. Company Information Table 36. Anterogen Co., Ltd. Business Overview Table 37. Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 39. Anterogen Co., Ltd. Recent Development Table 40. APAC Biotech Company Information Table 41. APAC Biotech Business Overview Table 42. APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 44. APAC Biotech Recent Development Table 45. Bristol-Myers Squibb Company Company Information Table 46. Bristol-Myers Squibb Company Business Overview Table 47. Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 49. Bristol-Myers Squibb Company Recent Development Table 50. CARsgen Therapeutics Holdings Limited Company Information Table 51. CARsgen Therapeutics Holdings Limited Business Overview Table 52. CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 54. CARsgen Therapeutics Holdings Limited Recent Development Table 55. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Company Information Table 56. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Business Overview Table 57. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 59. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Recent Development Table 60. Gilead Sciences, Inc. Company Information Table 61. Gilead Sciences, Inc. Business Overview Table 62. Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 64. Gilead Sciences, Inc. Recent Development Table 65. Green Cross Holdings Co., Ltd. (GC Cell) Company Information Table 66. Green Cross Holdings Co., Ltd. (GC Cell) Business Overview Table 67. Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 69. Green Cross Holdings Co., Ltd. (GC Cell) Recent Development Table 70. Healiva SA Company Information Table 71. Healiva SA Business Overview Table 72. Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 74. Healiva SA Recent Development Table 75. ImmunoACT Company Information Table 76. ImmunoACT Business Overview Table 77. ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 79. ImmunoACT Recent Development Table 80. Iaso Biotherapeutics Company Information Table 81. Iaso Biotherapeutics Business Overview Table 82. Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 84. Iaso Biotherapeutics Recent Development Table 85. Johnson & Johnson Company Information Table 86. Johnson & Johnson Business Overview Table 87. Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 89. Johnson & Johnson Recent Development Table 90. Lovance Biotherapeutics, Inc. Company Information Table 91. Lovance Biotherapeutics, Inc. Business Overview Table 92. Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 94. Lovance Biotherapeutics, Inc. Recent Development Table 95. Novartis AG Company Information Table 96. Novartis AG Business Overview Table 97. Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 99. Novartis AG Recent Development Table 100. Pharmicell Co., Ltd. Company Information Table 101. Pharmicell Co., Ltd. Business Overview Table 102. Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 104. Pharmicell Co., Ltd. Recent Development Table 105. Regrow Biosciences Pvt Ltd. Company Information Table 106. Regrow Biosciences Pvt Ltd. Business Overview Table 107. Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 109. Regrow Biosciences Pvt Ltd. Recent Development Table 110. Tegoscience Company Information Table 111. Tegoscience Business Overview Table 112. Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 114. Tegoscience Recent Development Table 115. Vericel Corporation Company Information Table 116. Vericel Corporation Business Overview Table 117. Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 119. Vericel Corporation Recent Development Table 120. W (Cayman) Therapeutics Co. Ltd. Company Information Table 121. W (Cayman) Therapeutics Co. Ltd. Business Overview Table 122. W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio Table 124. W (Cayman) Therapeutics Co. Ltd. Recent Development Table 125. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026) & (US$ Million) Table 126. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032) & (US$ Million) Table 127. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026) & (US$ Million) Table 128. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032) & (US$ Million) Table 129. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (US$ Million) & (2027-2032) Table 132. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026) & (US$ Million) Table 133. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032) & (US$ Million) Table 134. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026) & (US$ Million) Table 135. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032) & (US$ Million) Table 136. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021-2026) & (US$ Million) Table 138. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (US$ Million) & (2027-2032) Table 139. China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026) & (US$ Million) Table 140. China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032) & (US$ Million) Table 141. China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026) & (US$ Million) Table 142. China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032) & (US$ Million) Table 143. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026) & (US$ Million) Table 144. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032) & (US$ Million) Table 145. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026) & (US$ Million) Table 146. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032) & (US$ Million) Table 147. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Region (US$ Million) & (2021-2026) Table 149. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Region (US$ Million) & (2027-2032) Table 150. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026) & (US$ Million) Table 151. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032) & (US$ Million) Table 152. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026) & (US$ Million) Table 153. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032) & (US$ Million) Table 154. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021-2026) & (US$ Million) Table 156. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (US$ Million) & (2027-2032) Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Autologous Stem Cell & Non-stem Cell Therapies Image Figure 2. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 4. CAR-T Image Figure 5. Tumor Infiltrating Lymphocyte Image Figure 6. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Surgery Center Image Figure 10. Other Image Figure 11. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size (US$ Million) & (2021-2032) Figure 12. Global Autologous Stem Cell & Non-stem Cell Therapies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Autologous Stem Cell & Non-stem Cell Therapies Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Autologous Stem Cell & Non-stem Cell Therapies Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Type (2021-2032) Figure 19. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Application (2021-2032) Figure 22. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032) Figure 24. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032) Figure 25. North America Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Country (2021-2032) Figure 26. United States Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032) Figure 31. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032) Figure 32. Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Country (2021-2032) Figure 33. Germany Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032) Figure 43. China Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032) Figure 44. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032) Figure 46. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032) Figure 47. Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Region (2021-2032) Figure 48. Japan Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032) Figure 56. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032) Figure 57. SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Country (2021-2032) Figure 58. Brazil Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Autologous Stem Cell & Non-stem Cell Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T
  • Tumor Infiltrating Lymphocyte
Applications
  • Hospital
  • Surgery Center
  • Other
Companies covered
  • Anterogen Co., Ltd.
  • APAC Biotech
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Holdings Limited
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
  • Gilead Sciences, Inc.
  • Green Cross Holdings Co., Ltd. (GC Cell)
  • Healiva SA
  • ImmunoACT
  • Iaso Biotherapeutics
  • Johnson & Johnson
  • Lovance Biotherapeutics, Inc.
  • Novartis AG
  • Pharmicell Co., Ltd.
  • Regrow Biosciences Pvt Ltd.
  • Tegoscience
  • Vericel Corporation
  • W (Cayman) Therapeutics Co. Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Autologous Stem Cell & Non-stem Cell Therapies Market by Type
  3. 1.2.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CAR-T
  5. 1.2.3 Tumor Infiltrating Lymphocyte
  6. 1.3 Autologous Stem Cell & Non-stem Cell Therapies Market by Application
  7. 1.3.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Surgery Center
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Autologous Stem Cell & Non-stem Cell Therapies Market Dynamics
  1. 2.1 Autologous Stem Cell & Non-stem Cell Therapies Industry Trends
  2. 2.2 Autologous Stem Cell & Non-stem Cell Therapies Industry Drivers
  3. 2.3 Autologous Stem Cell & Non-stem Cell Therapies Industry Opportunities and Challenges
  4. 2.4 Autologous Stem Cell & Non-stem Cell Therapies Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market Perspective (2021-2032)
  2. 3.2 Global Autologous Stem Cell & Non-stem Cell Therapies Growth Trends by Region
  3. 3.2.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region (2021-2026)
  5. 3.2.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Players
  2. 4.1.1 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Players (2021-2026)
  3. 4.1.2 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Autologous Stem Cell & Non-stem Cell Therapies Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Autologous Stem Cell & Non-stem Cell Therapies Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Autologous Stem Cell & Non-stem Cell Therapies Key Players Headquarters & Area Served
  7. 4.4 Global Autologous Stem Cell & Non-stem Cell Therapies Players, Product Type & Application
  8. 4.5 Global Autologous Stem Cell & Non-stem Cell Therapies Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market CR5 and HHI
  11. 4.6.3 2025 Autologous Stem Cell & Non-stem Cell Therapies Tier 1, Tier 2, and Tier 3
5 Autologous Stem Cell & Non-stem Cell Therapies Market Size by Type
  1. 5.1 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2032)
  3. 5.3 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Type (2021-2032)
6 Autologous Stem Cell & Non-stem Cell Therapies Market Size by Application
  1. 6.1 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2032)
  3. 6.3 Global Autologous Stem Cell & Non-stem Cell Therapies Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Anterogen Co., Ltd.
  2. 7.1.1 Anterogen Co., Ltd. Company Information
  3. 7.1.2 Anterogen Co., Ltd. Business Overview
  4. 7.1.3 Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Anterogen Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  6. 7.1.5 Anterogen Co., Ltd. Recent Developments
  7. 7.2 APAC Biotech
  8. 7.2.1 APAC Biotech Company Information
  9. 7.2.2 APAC Biotech Business Overview
  10. 7.2.3 APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  11. 7.2.4 APAC Biotech Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  12. 7.2.5 APAC Biotech Recent Developments
  13. 7.3 Bristol-Myers Squibb Company
  14. 7.3.1 Bristol-Myers Squibb Company Company Information
  15. 7.3.2 Bristol-Myers Squibb Company Business Overview
  16. 7.3.3 Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bristol-Myers Squibb Company Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  18. 7.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 7.4 CARsgen Therapeutics Holdings Limited
  20. 7.4.1 CARsgen Therapeutics Holdings Limited Company Information
  21. 7.4.2 CARsgen Therapeutics Holdings Limited Business Overview
  22. 7.4.3 CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  23. 7.4.4 CARsgen Therapeutics Holdings Limited Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  24. 7.4.5 CARsgen Therapeutics Holdings Limited Recent Developments
  25. 7.5 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
  26. 7.5.1 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Company Information
  27. 7.5.2 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Business Overview
  28. 7.5.3 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  30. 7.5.5 Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.) Recent Developments
  31. 7.6 Gilead Sciences, Inc.
  32. 7.6.1 Gilead Sciences, Inc. Company Information
  33. 7.6.2 Gilead Sciences, Inc. Business Overview
  34. 7.6.3 Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Gilead Sciences, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  36. 7.6.5 Gilead Sciences, Inc. Recent Developments
  37. 7.7 Green Cross Holdings Co., Ltd. (GC Cell)
  38. 7.7.1 Green Cross Holdings Co., Ltd. (GC Cell) Company Information
  39. 7.7.2 Green Cross Holdings Co., Ltd. (GC Cell) Business Overview
  40. 7.7.3 Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Green Cross Holdings Co., Ltd. (GC Cell) Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  42. 7.7.5 Green Cross Holdings Co., Ltd. (GC Cell) Recent Developments
  43. 7.8 Healiva SA
  44. 7.8.1 Healiva SA Company Information
  45. 7.8.2 Healiva SA Business Overview
  46. 7.8.3 Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Healiva SA Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  48. 7.8.5 Healiva SA Recent Developments
  49. 7.9 ImmunoACT
  50. 7.9.1 ImmunoACT Company Information
  51. 7.9.2 ImmunoACT Business Overview
  52. 7.9.3 ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  53. 7.9.4 ImmunoACT Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  54. 7.9.5 ImmunoACT Recent Developments
  55. 7.10 Iaso Biotherapeutics
  56. 7.10.1 Iaso Biotherapeutics Company Information
  57. 7.10.2 Iaso Biotherapeutics Business Overview
  58. 7.10.3 Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Iaso Biotherapeutics Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  60. 7.10.5 Iaso Biotherapeutics Recent Developments
  61. 7.11 Johnson & Johnson
  62. 7.11.1 Johnson & Johnson Company Information
  63. 7.11.2 Johnson & Johnson Business Overview
  64. 7.11.3 Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Johnson & Johnson Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  66. 7.11.5 Johnson & Johnson Recent Developments
  67. 7.12 Lovance Biotherapeutics, Inc.
  68. 7.12.1 Lovance Biotherapeutics, Inc. Company Information
  69. 7.12.2 Lovance Biotherapeutics, Inc. Business Overview
  70. 7.12.3 Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Lovance Biotherapeutics, Inc. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  72. 7.12.5 Lovance Biotherapeutics, Inc. Recent Developments
  73. 7.13 Novartis AG
  74. 7.13.1 Novartis AG Company Information
  75. 7.13.2 Novartis AG Business Overview
  76. 7.13.3 Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Novartis AG Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  78. 7.13.5 Novartis AG Recent Developments
  79. 7.14 Pharmicell Co., Ltd.
  80. 7.14.1 Pharmicell Co., Ltd. Company Information
  81. 7.14.2 Pharmicell Co., Ltd. Business Overview
  82. 7.14.3 Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Pharmicell Co., Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  84. 7.14.5 Pharmicell Co., Ltd. Recent Developments
  85. 7.15 Regrow Biosciences Pvt Ltd.
  86. 7.15.1 Regrow Biosciences Pvt Ltd. Company Information
  87. 7.15.2 Regrow Biosciences Pvt Ltd. Business Overview
  88. 7.15.3 Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Regrow Biosciences Pvt Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  90. 7.15.5 Regrow Biosciences Pvt Ltd. Recent Developments
  91. 7.16 Tegoscience
  92. 7.16.1 Tegoscience Company Information
  93. 7.16.2 Tegoscience Business Overview
  94. 7.16.3 Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Tegoscience Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  96. 7.16.5 Tegoscience Recent Developments
  97. 7.17 Vericel Corporation
  98. 7.17.1 Vericel Corporation Company Information
  99. 7.17.2 Vericel Corporation Business Overview
  100. 7.17.3 Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Vericel Corporation Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  102. 7.17.5 Vericel Corporation Recent Developments
  103. 7.18 W (Cayman) Therapeutics Co. Ltd.
  104. 7.18.1 W (Cayman) Therapeutics Co. Ltd. Company Information
  105. 7.18.2 W (Cayman) Therapeutics Co. Ltd. Business Overview
  106. 7.18.3 W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Revenue and Gross Margin (2021-2026)
  107. 7.18.4 W (Cayman) Therapeutics Co. Ltd. Autologous Stem Cell & Non-stem Cell Therapies Product Portfolio
  108. 7.18.5 W (Cayman) Therapeutics Co. Ltd. Recent Developments
8 North America
  1. 8.1 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue (2021-2032)
  2. 8.2 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2032)
  3. 8.2.1 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026)
  4. 8.2.2 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032)
  5. 8.3 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032)
  6. 8.4 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2032)
  7. 8.4.1 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026)
  8. 8.4.2 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032)
  9. 8.5 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032)
  10. 8.6 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country
  11. 8.6.1 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021-2026)
  13. 8.6.3 North America Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue (2021-2032)
  2. 9.2 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2032)
  3. 9.2.1 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026)
  4. 9.2.2 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032)
  5. 9.3 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032)
  6. 9.4 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2032)
  7. 9.4.1 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026)
  8. 9.4.2 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032)
  9. 9.5 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032)
  10. 9.6 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country
  11. 9.6.1 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021-2026)
  13. 9.6.3 Europe Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Autologous Stem Cell & Non-stem Cell Therapies Revenue (2021-2032)
  2. 10.2 China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2032)
  3. 10.2.1 China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026)
  4. 10.2.2 China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032)
  5. 10.3 China Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032)
  6. 10.4 China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2032)
  7. 10.4.1 China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026)
  8. 10.4.2 China Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032)
  9. 10.5 China Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue (2021-2032)
  2. 11.2 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2032)
  3. 11.2.1 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026)
  4. 11.2.2 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032)
  5. 11.3 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032)
  6. 11.4 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2032)
  7. 11.4.1 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026)
  8. 11.4.2 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032)
  9. 11.5 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032)
  10. 11.6 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country
  11. 11.6.1 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021-2026)
  13. 11.6.3 Asia Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue (2021-2032)
  2. 12.2 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Type (2027-2032)
  5. 12.3 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Application (2027-2032)
  9. 12.5 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country
  11. 12.6.1 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Autologous Stem Cell & Non-stem Cell Therapies Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst